Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


MedImmune Expands Oncology Pipeline With Therapeutic Protein Technology

This article was originally published in The Pink Sheet Daily

Executive Summary

Agreement with Avidia is firm's eleventh licensing deal or acquisition of validated targets for product development in the last 12 months.

You may also be interested in...

Oncologic Committee To Meet Nov. 8 On Accelerated Approval Commitments

Committee to revisit drugs with postmarketing commitments previously reviewed in 2003 and give advice for conduct of confirmatory studies for sponsors with newly approved drugs.

MedImmune Plans To Expand Sales Force As It Reacquires Synagis Promotion Rights

Abbott will release co-promotion rights for the respiratory syncytial virus therapy effective June 30, 2006.

Amgen Raises Profile Of Oncology Therapeutics Unit

Newly promoted VP David Parkinson, MD, will oversee reconfigured oncology unit with separate supportive care and therapeutics groups.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts